share_log

藥明巨諾-B:截至二零二四年十一月三十日止月份之股份發行人的證券變動月報表

JW THERAP-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024

HKEX ·  Dec 5, 2024 16:29

Summary by Moomoo AI

截至2024年11月30日,藥明巨諾的法定/註冊股本保持不變,總額為50,000美元。已發行股份數量從415,436,268股增加至415,446,268股,增加了10,000股,無庫存股份變動。這些變動主要來自於首次公開發售前激勵計劃的行使,涉及10,000股新股的發行。在股份期權計劃中,首次公開發售前激勵計劃的行使價為0.0001美元,導致10,000股新股的發行。首次公開發售後激勵計劃中,部分期權失效,總計減少24,753股期權。所有變動均已獲得董事會批准,並符合香港聯交所的上市規則。公司確認所有相關法律及監管要求均已遵循,並已完成所有必要的文件存檔。主席李怡平代表公司提交了此報告,確保所有程序的合規性。
截至2024年11月30日,藥明巨諾的法定/註冊股本保持不變,總額為50,000美元。已發行股份數量從415,436,268股增加至415,446,268股,增加了10,000股,無庫存股份變動。這些變動主要來自於首次公開發售前激勵計劃的行使,涉及10,000股新股的發行。在股份期權計劃中,首次公開發售前激勵計劃的行使價為0.0001美元,導致10,000股新股的發行。首次公開發售後激勵計劃中,部分期權失效,總計減少24,753股期權。所有變動均已獲得董事會批准,並符合香港聯交所的上市規則。公司確認所有相關法律及監管要求均已遵循,並已完成所有必要的文件存檔。主席李怡平代表公司提交了此報告,確保所有程序的合規性。
As of November 30, 2024, the regulary/registered share capital of Mengjevo remained unchanged, totaling $50,000. The number of shares issued increased from 415,436,268 shares to 415,446,268 shares, an increase of 10,000 shares, with no change in stock. These changes resulted primarily from the implementation of the incentive program prior to the initial public offering, involving the issuance of 10,000 new shares.In the stock option plan, the exercise price of the incentive plan before the initial public offering is $0.0001, resulting in the issuance of 10,000 new shares. In the Initial Public Offering Incentive Program, some options expired, resulting in a total reduction of 24,753 share options. All changes have been approved by the Board of Directors and are in compliance with the Listing Rules of the HKEx.The Company verifies that all relevant legal and regulatory requirements have been complied with and that all necessary documentation archives have been completed. Chairman Li Yiping submitted this report on behalf of the company to ensure compliance of all procedures.
As of November 30, 2024, the regulary/registered share capital of Mengjevo remained unchanged, totaling $50,000. The number of shares issued increased from 415,436,268 shares to 415,446,268 shares, an increase of 10,000 shares, with no change in stock. These changes resulted primarily from the implementation of the incentive program prior to the initial public offering, involving the issuance of 10,000 new shares.In the stock option plan, the exercise price of the incentive plan before the initial public offering is $0.0001, resulting in the issuance of 10,000 new shares. In the Initial Public Offering Incentive Program, some options expired, resulting in a total reduction of 24,753 share options. All changes have been approved by the Board of Directors and are in compliance with the Listing Rules of the HKEx.The Company verifies that all relevant legal and regulatory requirements have been complied with and that all necessary documentation archives have been completed. Chairman Li Yiping submitted this report on behalf of the company to ensure compliance of all procedures.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more